Aignostics has announced €31.4M Series B to advance AI precision medicine and create new computational pathology products and services in partnership with the Mayo Clinic.
Aignostics takes a seven-figure round to further AI in pathology:
Berlin-based computational pathology AI company Aignostics has raised €31.4 million in a Series B round. In this financing round, ATHOS, joined by Mayo Clinic and HTGF, aims to help Aignostics scale up in the United States and introduce new Artificial Intelligence applications to biopharmaceutical industries. Furthermore, Aignostics has already raised over $55 million, and as a result, it now has the necessary conditions to reinforce its AI models and expand its services.
Related Content: Pathology Software and Service Startup Deciphex Raises €3.9M
With the level of implementation of precision medicine ever rising, biodiversity firms are relying on AI to boost drug production and diagnosis. By contrast, Aignostics has one of the highest accuracy and generalization capabilities, making computational pathology more reliable. This latest funding will make targeted identification, translational research, and companion diagnostics (CDx) for medical development a reality at Aignostics.
Partnerships for Change and New Directions:
Aignostics collaborates with the Mayo Clinic to build pathologists’ basic pathology models, such as the recently introduced RudolfV. Through this model, the committee can design cost-effective promoting algorithms that are easily implemented in real-world environments. Furthermore, by leveraging key social capital and growth strategies, Aignostics aims to make significant strides in the field of personalized and prognosticated medicine.
Possibilities for the Future in Computational Pathology:
Backed by investors including Wellington Partners and Boehringer Ingelheim Venture Fund, Aignostics has been developing a highly integrated, AI-powered platform that has the potential to greatly transform pharma R&D. Furthermore, the company’s commitment to transparency and enhanced quality has earned significant trust from investors. As a result, by 2024, Aignostics will revolutionize AI usage in the precision medicine process, offering practical and meaningful solutions for the healthcare industry’s future.
